Advertisement

Topics

Urigen Pharmaceuticals Inc Strategic SWOT Analysis Review [Report Updated: 25042018] Prices from USD $125

10:58 EDT 25 Aug 2018 | BioPortfolio Reports

Urigen Pharmaceuticals Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.


This uptotheminute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


Scope


Business description A detailed description of the company's operations and business divisions.

Corporate strategy GlobalData's summarization of the company's business strategy.

SWOT analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.

Key manufacturing facilities A list of key manufacturing facilities of the company.


Highlights


Urigen Pharmaceuticals Inc Urigen is a specialty pharmaceutical company that develops and commercializes therapeutic products for urological disorders. The company focuses on developing innovative products for amelioration of urethritis, painful bladder syndrome PBS, nocturia and over active bladder OAB. Its pipeline includes its flagship candidate, URG101, being developed for the painful bladder syndrome/interstitial cystitis. The company licensed URG101, is a proprietary combination therapy for the relief of pain of bladder. Its other product candidate, URG501, is in preclinical development. Urigen is headquartered in North Brunswick, New Jersey, the US.


Reasons to Buy


Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.


Note: Some sections may be missing if data is unavailable for the company.

Original Article: Urigen Pharmaceuticals Inc Strategic SWOT Analysis Review [Report Updated: 25042018] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "Urigen Pharmaceuticals Inc Strategic SWOT Analysis Review [Report Updated: 25042018] Prices from USD $125"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...